EP Patent

EP0393781A2 — Dopamine pro-drug

Assigned to Zambon Group SpA · Expires 1990-10-24 · 36y expired

What this patent protects

A monophosphorylated L-dopa ester of formula (wherein the asterisk, R, R₁, R₂ and R₃ have the meanings shown in the description), salts thereof with pharmaceutically acceptable acids or bases, a process for the preparation thereof and a pharmaceutical composition containin…

USPTO Abstract

A monophosphorylated L-dopa ester of formula (wherein the asterisk, R, R₁, R₂ and R₃ have the meanings shown in the description), salts thereof with pharmaceutically acceptable acids or bases, a process for the preparation thereof and a pharmaceutical composition containing said compound or a salt thereof are described. The compound of formula I and the salts thereof are useful in the treatment of Parkinson's disease, renal failure, heart failure and hypertension.

Drugs covered by this patent

Patent Metadata

Patent number
EP0393781A2
Jurisdiction
EP
Classification
—
Expires
1990-10-24
Drug substance claim
No
Drug product claim
No
Assignee
Zambon Group SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.